Brief: Fibrogen Announces Topline Results From Lelantos-2, A Phase 3 Clinical Study Of Pamrevlumab In Ambulatory Duchenne Muscular Dystrophy

Kyntra Bio

29/08/2023 22:44

Aug 29 (Reuters) - FibroGen Inc  FGEN.O :
    * FIBROGEN ANNOUNCES TOPLINE RESULTS FROM LELANTOS-2, A
PHASE 3
CLINICAL STUDY OF PAMREVLUMAB IN AMBULATORY DUCHENNE MUSCULAR
DYSTROPHY
    * FIBROGEN INC: STUDY DID NOT MEET PRIMARY ENDPOINT
    * FIBROGEN INC: PAMREVLUMAB WAS GENERALLY SAFE AND WELL
TOLERATED
    * FIBROGEN INC: TREATMENT-EMERGENT SERIOUS ADVERSE EVENTS
WERE
OBSERVED IN 8.3% OF PATIENTS IN PAMREVLUMAB GROUP AND 2.8% OF
PATIENTS IN PLACEBO GROUP
    * FIBROGEN INC: IN PROCESS OF EVALUATING TOTALITY OF DATA TO
DETERMINE NEXT STEPS FOR PROGRAM

Source text for Eikon:  ID:nGNX8NtLmc 
Further company coverage:  FGEN.O 

 ((Reutersbriefs@thomsonreuters.com;))